Polymorphism of CYP3A4*18 is associated with anti-tuberculosis drug-induced hepatotoxicity

被引：0

作者：

Lee, Shih-Wei ^{[1
,2
]}

Chen, Pei-Tzu ^{[3
]}

Liu, Chi-Wei ^{[4
]}

Li, Yuan-Hsu ^{[5
]}

Wu, Lawrence Shih-Hsin ^{[3
]}

机构：

[1] Taoyuan Gen Hosp, Dept Chest Med, Dept Hlth & Welf, Taoyuan 33004, Taiwan

[2] Yuanpei Univ Med Technol, Dept Nursing, Hsinchu 30015, Taiwan

[3] China Med Univ, Grad Inst Biomed Sci, Taichung 404328, Taiwan

[4] Taoyuan Gen Hosp, Translat Med Ctr, Dept Hlth & Welf, Taoyuan 33004, Taiwan

[5] Taoyuan Gen Hosp, Dept Lab Med, Dept Hlth & Welf, Taoyuan 33004, Taiwan

来源：

PHARMACOGENOMICS | 2024年 / 25卷 / 5-6期

关键词：

anti-tuberculosis drugs; cytochrome P450 genes; hepatotoxicity; LIVER-INJURY; GENETIC POLYMORPHISMS; CYTOCHROME-P450; EXPRESSION; RIFAMPIN; PHARMACOKINETICS; PYRAZINAMIDE; HEPATITIS; VARIANTS; CYP3A4;

D O I：

10.1080/14622416.2024.2346069

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aim: The association between cytochrome P450 (CYP) gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity (ATDH) was investigated in patients with or without pre-existing liver diseases (PLD). Materials & methods: We followed 164 tuberculosis subjects, 58 with PLD and 106 without PLD. Polymorphisms in CYP2D6, CYP2C9, CYP2C19, CYP3A4 and CYP3A5 were analyzed using the TaqMan (R) SNP genotyping assay. Results: The CYP3A4*18 heterozygous genotype was associated with ATDH (OR: 3.24, 95% CI: 1.06-9.86) regardless of PLD presence. Among subjects without PLD, CYP3A4*18 heterozygotes had significantly higher ATDH risk (OR: 9.10, 95% CI: 1.56-53.16). Conversely, in the PLD group, CYP3A4*18 heterozygotes had lower ATDH risk (OR: 0.21, 95% CI: 0.05-0.98). Conclusion: CYP3A4*18 genotype is linked to ATDH in tuberculosis patients, with differential effects based on PLD presence.

引用

页码：241 / 247

页数：7

共 33 条

[1] Update on rifampin, rifabutin, and rifapentine drug interactions [J].

Baciewicz, Anne M. ;

Chrisman, Cary R. ;

Finch, Christopher K. ;

Self, Timothy H. .

CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (01) :1-12

[2]

BENICHOU C, 1990, J HEPATOL, V11, P272

[3] Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver:: Consequences for enzyme expression and busulfan conjugation [J].

Bredschneider, M ;

Klein, K ;

Mürdter, TE ;

Marx, C ;

Eichelbaum, M ;

Nüssler, AK ;

Neuhaus, P ;

Zanger, UM ;

Schwab, M .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (06) :479-487

[4] Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes [J].

Cao, Lei ;

Greenblatt, David J. ;

Kwara, Awewura .

DRUG METABOLISM AND DISPOSITION, 2017, 45 (09) :1035-1043

[5]

Dai D, 2001, J PHARMACOL EXP THER, V299, P825

[6]

DURAND F, 1995, HEPATOLOGY, V21, P929, DOI 10.1002/hep.1840210407

[7] Anti-infectives - Adverse reactions to first-line antituberculosis drugs [J].

Forget, Eric J. ;

Menzies, Dick .

EXPERT OPINION ON DRUG SAFETY, 2006, 5 (02) :231-249

[8]

FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151

[9]

[郭桐君 Guo Tongjun], 2016, [中华疾病控制杂志, Chinese Journal of Disease Control & Prevention], V20, P897

[10] Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver [J].

Jamwal, Rohitash ;

de la Monte, Suzanne M. ;

Ogasawara, Ken ;

Adusumalli, Sravani ;

Barlock, Benjamin B. ;

Akhlaghi, Fatemeh .

MOLECULAR PHARMACEUTICS, 2018, 15 (07) :2621-2632

← 1 2 3 4 →